Havrix Junior

Havrix Junior is an injectable suspension vaccine containing inactivated hepatitis A virus and algeldrate as the active ingredient. It is supplied in a strength appropriate for pediatric use and is administered intramuscularly. The product is authorized in the European Union and is available by prescription for the prevention of hepatitis A infection in children. The formulation is designed to stimulate an immune response that provides protection against hepatitis A virus.

Havrix Junior is indicated for active immunisation against hepatitis A virus in children.

- Primary prevention of hepatitis A infection in children aged 1 year and older. - Use in routine childhood vaccination programmes where hepatitis A risk is recognised. - Administration to children who have not previously received hepatitis A vaccine. - May be given to children travelling to regions with high hepatitis A endemicity. - Can be used in outbreak control settings to protect susceptible paediatric populations.

The safety profile of Havrix Junior reflects the typical reactions observed with inactivated viral vaccines.

Common: - Mild pain, redness or swelling at the injection site. - Low‑grade fever. - Headache. - Fatigue.

Serious: - Allergic reactions such as urticaria, angioedema or anaphylaxis. - Rare neurologic events (e.g., Guillain‑Barré syndrome). - Persistent high fever.

Precautions for Havrix Junior focus on patient history, immune status and proper administration technique.

- Assess for severe allergic reaction to any component, especially algeldrate. - Defer vaccination in individuals with acute moderate or severe illness. - Use caution in immunocompromised children; vaccine may be less effective. - Post‑vaccination, monitor for signs of anaphylaxis for at least 15 minutes. - Do not administer intravascularly; ensure correct intramuscular route. - Pregnancy and breastfeeding status should be discussed with a healthcare professional.

Havrix Junior has limited documented drug interactions, but certain substances may affect immune response or increase adverse‑event risk.

Avoid: - Live viral vaccines administered within 4 weeks before or after Havrix Junior. - Immunoglobulin or blood products given within 2 weeks of vaccination, which may reduce antibody response.

Use with caution: - Immunosuppressive therapies (e.g., corticosteroids) that could diminish vaccine efficacy. - Antipyretics taken prophylactically may mask low‑grade fever. - Chronic medical conditions requiring ongoing medication should be reviewed by a clinician.